A carregar...
New Therapeutic Targets in Idiopathic Pulmonary Fibrosis. Aiming to Rein in Runaway Wound-Healing Responses
Idiopathic pulmonary fibrosis (IPF) is a devastating disease, with a median survival as short as 3 years from the time of diagnosis and no pharmacological therapies yet approved by the U.S. Food and Drug Administration. To address the great unmet need for effective IPF therapy, a number of new drugs...
Na minha lista:
| Publicado no: | Am J Respir Crit Care Med |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Thoracic Society
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4299574/ https://ncbi.nlm.nih.gov/pubmed/25090037 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1164/rccm.201403-0509PP |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|